Winter 2018
Liebert Link News and Information for Librarians
News & Information Featured Publication In the News Resources Contact


Mary Ann Liebert

Every day in recent weeks has brought news in the field of biotechnology, which is the rubric for R&D in the life sciences. Some of the news is exciting and promising, and some of it is surprising and unsettling. Among the good news was an announcement from the NIH that they are committing $190M to Somatic Cell Genome Editing—a major application of CRISPR technology that has the power to revolutionize medicine. While talks recently have centered on lack of research dollars in major areas of research, this commitment from the federally funded agency is very good news. However, on the other end of the spectrum was the news that the U.S. is no longer in the top ten “innovative countries” according to Bloomberg and that, at the same time, China is racing towards a leadership position in biotech research and technology output.

Last month, my long-time friend and President of Research!America, Mary Woolley, penned an urgent “wake-up call”: “U.S. investment in R&D is treated like an afterthought — with a broken budget system to boot,” Mary wrote. “The fact that critically important government functions are in a ‘state of suspended animation,’ as Ellie [Dehoney, Vice President of Policy and Advocacy at Research!America] put it in a recent Hill article, is an excellent reason to speak out if you have not yet done so, and to speak out again, if you already have.”

Our battle for federal funding for research is an ongoing one, and speaking up and advocating for same is not a one-time proposition. Without federal support, new and important research imperatives such as CRISPR will be in jeopardy. As you may already know, The CRISPR Journal will make a very authoritative debut in February in Boston. Bioelectricity, an influential and dynamic meeting place for the rapidly growing bioelectricity community and the peer-reviewed journal of record, will make its debut this summer, and, in fact, this field may hold the greatest promise of all. We must ensure that our endeavors are well supported to ensure their contribution to the healthcare of the future.

The United States must reemerge as a biotech leader. Researchers and members of the biotechnology community must fight for the funding needed to ensure this outcome, and I hope that the library community will makes its very important voice known as well, again and again.

Mary Ann
Founder, President, and CEO

Sales News & Information

Special Offer as The CRISPR Journal’s Inaugural Issue is About to Go to Press!

Contact Wendy Newsham, Director of Institutional Sales and Business Development, directly to subscribe to The CRISPR Journal by February 15 and we’ll send you up to 20 copies of the limited edition first issue, which includes a commissioned work of art on the front cover!

As ever, your account representative is ready to help you subscribe to The CRISPR Journal, renew existing subscriptions, learn about additional titles relevant to your collection, and to advise you of special offers and discounts.

Reach out to your Sales Representative or contact us today to learn more!

Journal News & Information

The CRISPR Journal: First Content Published Online!

CRISPR Journal Cover

We are thrilled to share the first content to be published in The CRISPR Journal! Take a peek at the first articles to go live ahead of the publication of Vol. 1, Issue 1 next month.

Don’t let your researchers miss a single article — contact your account representative and subscribe now!

New Title Coming in 2019 — Bioelectricity

Bioelectricity, an influential and dynamic meeting place for the rapidly growing bioelectricity community and the peer-reviewed journal of record, will be published by Mary Ann Liebert, Inc. Spearheaded by Editor-in-Chief, Dany Spencer Adams, PhD, Tufts University, Bioelectricity will be published online and in print with open access options and provide an authoritative, high-profile forum for groundbreaking original research papers, review articles, and captivating front matter, debate, and commentary. A preview issue of the Journal is planned for summer 2018.

Authoritative Associate Editors include Annarosa Arcangeli, MD, PhD, University of Florence School of Medicine, Emily Bates, PhD, University of Colorado Denver School of Medicine, Mustafa Djamgoz, PhD, Imperial College London, Richard Kramer, PhD, University of California, Berkeley, Michael Levin, PhD, Tufts University, Richard Nuccitelli, PhD, Pulse Biosciences Inc., Ann Rajnicek, BS, PhD, FRSB, University of Aberdeen, and Min Zhao, PhD, School of Medicine, UC Davis.

Read the launch announcement for Bioelectricity here.

Autism in Adulthood Launching in 2019

Autism in Adulthood, a new peer-reviewed journal dedicated to biological, neurological, psychological, cognitive, emotional, and behavioral research and scholarship on the most pressing issues affecting adults on the autism spectrum, from young adulthood to later life. The Journal will be the premier source for authoritative original research, in-depth analysis, and inter-professional dialogue. A special mini-preview issue of the Journal will appear in Spring 2018.

Autism in Adulthood will be led by Editor-in-Chief Christina Nicolaidis, MD, MPH, who co-directs the Academic Autism Spectrum Partnership in Research and Education (AASPIRE) and has joint appointments at Portland State University and Oregon Health & Science University. Dr. Nicolaidis will guide an established group of thought leaders on the Editorial Board, including Simon Baron-Cohen (University of Cambridge, UK), Akio Wakabayashi (Chiba University, Japan), Clarissa Kripke (University of California, San Francisco), Alexia Rattazzi (PANAACEA, Buenos Aires, Argentina), Lisa Croen (Kaiser Permanente Northern California), Jeremy Parr (Newcastle University, UK), Scott Robertson (US Department of Labor), and Associate Editor Dora Raymaker (Portland State University).

Click here to receive alerts for forthcoming information about Autism in Adulthood.

New Editorial Leadership

JICR Journal Cover

Michael Gale, Jr., PhD will assume the role of Editor-in-Chief of Journal of Interferon & Cytokine Research in March 2018. Dr. Gale is a Professor in the Department of Immunology at The University of Washington, School of Medicine, where he is the Director of the Center for Innate Immunity and Immune Disease. He is an Adjunct Professor in the Department of Microbiology and the Department of Global Health, is a Member of the University of Washington/Fred Hutchinson Cancer Research Center Consortium, and is an Affiliate Member of the FHCRC Clinical Research Division and the Seattle Cancer Care Alliance. Dr. Gale is also a Core Staff member of the Washington National Primate Research Center, and serves as Co-Director of the University of Washington Center for Emerging and Re-emerging Infectious Diseases.

Journal of Interferon & Cytokine Research, now in its 38th year, was the first journal published by Mary Ann Liebert, Inc., publishers. As such, it will always be very meaningful to the publisher.

The CRISPR Journal: Editor-in-Chief Appointed

CRISPR Journal Cover

In November, Dr. Rodolphe Barrangou was named Editor-in-Chief of The CRISPR Journal. Dr. Barrangou currently serves as the Todd R. Klaenhammer Distinguished Scholar in Probiotics Research and Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University (NCSU). He is one of the early pioneers of CRISPR, having made major contributions during his years working at DuPont, prior to joining the NCSU faculty in 2013.

Dr. Barrangou guides an established group of luminaries who have thrown their support behind The CRISPR Journal by joining the Editorial Board, including Jennifer Doudna (HHMI/UC Berkeley), Emmanuelle Charpentier (Max Planck Institute, Berlin), George Church (Harvard Medical School), Virginijus Siksnys (Vilnius Institute of Technology), and Eugene Koonin (NCBI).

In the News

A selection of some of our latest, groundbreaking research making headlines right now:

Gene Delivery of Drugs Directly into Arthritic Joints Is Making the Leap to Patients

Timothy Ray Brown, Cured of HIV, Rallies Public to Support Research Funding

Researchers Develop Molecular Probes to Allow Non-Destructive Analysis of Bioengineered Cartilage

Early Results Reported on e-Health Tool to Prevent Opioid Overdose

3D-Printed Underwater Vortex Sensor Mimics Whiskers of Sea Animal

New Method Stabilizes siRNAs Without Affecting Gene Silencing Activity

Can CranioSacral Therapy Improve Symptoms of Concussion and Mild Traumatic Brain Injury Among Football Players?

The Academy of Breastfeeding Medicine Issues Guidance on Informal Milk Sharing for Healthy Term infants

The CRISPR Journal Debuts Online Content with Francisco Mojica Interview, Patent Outlook from Jacob Sherkow, and Inaugural Editorial from Editor-in-Chief Rodolphe Barrangou

View our complete list of press releases here.

This Issue’s Featured Journal:

ADT Journal Cover

ASSAY and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application. The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section presenting techniques and tools for finding new uses for approved drugs — particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Bruce Melancon, PhD, University of Notre Dame; and other leading investigators. The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U. The Journal is essential for libraries serving drug discovery and developmental scientists, pharmaceutical and biotechnology researchers, and disease foundation specialists, among others.

Contact us to learn more about adding ASSAY and Drug Development Technologies to your collection.

Come See Us

Stop by our booth to pick up materials, meet our staff, and more at these upcoming conferences:

VALA 2018 — Represented by Burgundy
February 13–15, 2018; Melbourne, Australia

Electronic Resources & Libraries Conference
March 4–7, 2018; Austin, TX

UKSG 41st. Annual Conference and Exhibition
April 9–11, 2018; Glasgow, Scotland

Sales Call!

Dispatches from Wendy Newsham, Director of Institutional Sales and Business Development

Wendy Newsham  

In case you haven’t heard, we’re launching a new journal: The CRISPR Journal.

I’ve been in scholarly publishing nearly 15 years and have never seen so much buzz and anticipation surrounding the launch of a new journal. But why all the buzz?! Sure, we’ve got a cracker jack marketing team, but in this case, the whole crew of them could sit on their hands and this journal would be still be the talk of the town. So why is that?

I think we could start with the obvious: it’s a cool science, genetic editing. I might not have my jetpack as promised in all those futuristic novels I read as a kid, but we do have genetic editing. It’s real, it’s happening, and it’s called CRISPR.

Plus, who doesn’t just love saying “CRISPR”? It’s a fun word (short for Clustered Regularly Interspaced Short Palindromic Repeats) and knowing what it’s about makes you feel very hip and cool. I’m a 50-year-old New Englander with a degree in English and I’ll tell you, this is my supercalifragilisticexpialidocious. Hip and cool is tough for someone like me to achieve, but my newfound fascination of all things CRISPR has catapulted me into …never mind, my teenagers may read this. While the word is definitely fun and intriguing, the science is even more so, and it’s a science that everyone can understand (even an English major!). When we decided to launch this journal last spring and our Executive Editor, Dr. Kevin Davies, started recruiting the Editorial Board members, he was ecstatic when Jennifer Doudna, considered to be the leading “Hero of CRISPR,” accepted. He told me she had written an incredible book that told her story in a way that made it possible for the general public to understand the science. Challenge accepted! I Primed myself a copy (hardcover, of course) of A Crack in Creation by Jennifer Doudna and Samuel Sternberg, and I curled up in my reading chair to delve into the great unknown. You know what? It’s a great book! This story, and the science, made a lot of sense to me. And if you can't tell, I’m now a CRISPR groupie!

Further justification for the hoopla is the first-class Editorial Board. You’ve already read about them in the News above, and even non-scientists suck in their breath a little when we start to roll down the list of luminaries from around the globe who are enthusiastically on-board for the launch and ongoing publication of a journal dedicated to their science. What’s more, the journal is not only going to cover scientific research and application with peer-reviewed original research, however, it is also going to include in-depth commentary on the legal and ethical issues of this emerging technology. In fact, Jacob Sherkow of New York Law School is included on the Editorial Board.

And that leads to another reason why this journal is so exciting: CRISPR science touches literally every realm of bioscience — human, animal, plant, food — everything. I was talking about The CRISPR Journal to my sister-in-law, an Assistant Professor of Molecular and Human Genetics at Baylor College of Medicine, and she said that she modified her curriculum to include CRISPR because this science is destined to make it to clinical application faster than any other in history. It's that big a deal. “This is a very momentous time for the CRISPR field, and The CRISPR Journal provides a voice and unifying common denominator to the various scientific disciplines that constitute the CRISPR community. I am very excited to be part of the Mary Ann Liebert team and have the opportunity to cover all aspects of the CRISPR field,” says Dr. Barrangou.

And I'm not the only one champing at the bit — the day we issued the press release announcing the launch, I personally received emails and phone calls from corporations and institutions requesting subscriptions — we weren’t even scheduled to publish a paper for another 8 months! That is one of the major assets we have here at Mary Ann Liebert; not only do we continue to publish incredibly important papers in our core journals (Journal of Neurotrauma, Thyroid, Diabetes Technology & Therapeutics, Tissue Engineering, Human Gene Therapy, etc.) but we have incredible foresight and the ability to launch journals focusing on critical emerging science, such as CRISPR, and our recently announced for 2019, Bioelectricity. This is a key differentiator that has contributed to our ongoing success.

So, bookmark this pageThe CRISPR Journal is coming!
In fact, you can take a look at the first release of articles, now available online ahead-of-print!


On the Road

Charlerston Conference

We returned to the Charleston Conference in 2017 and enjoyed meeting so many of you in person and learning a lot in sessions! See you in 2018!

Contact Us

We'd love to hear from you!

For questions about our products, including quotes on collections and to set up trial access:
Wendy Newsham
Director of Institutional Sales and Business Development

For questions about your online account:

To drop us a line and let us know what you think about our newsletter:
Click here


For comprehensive information specifically for libraries, including account management, customer support, catalogs, and detailed product information, please visit our Librarian Resource Center.

Refine your Email Preferences at My Liebert Connect

© 2018 Mary Ann Liebert, Inc., publishers. All Rights Reserved
140 Huguenot Street, New Rochelle, NY 10801